Natera AI Stock Analysis
Natera (45E) AI Stock Analysis
Natera
(Berlin:45E)
No summary available
Natera (45E) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 41.98B
- Dividend Yield
- ―
- Average Volume (3M)
- 59
- Price to Earnings (P/E)
- -253.9
- Beta (1Y)
- 0.17
- Revenue Growth
- 31.00%
- EPS Growth
- 51.97%
- Country
- Germany
- Employees
- 6,138
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Natera Business Overview & Revenue Model
Company Description
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromoso...
Natera Earnings Call Summary
The call was strongly positive. Natera reported record testing volumes, more than 40% revenue growth excluding true-ups, accelerating MRD adoption, improving underlying gross margins, cash generation, narrowed losses, new Medicare coverage, progress toward a Japan launch, strong clinical evidence, and raised full-year guidance. The main challenges were higher planned operating expenses, near-term COGS pressure from newer products, uncertain timing for additional reimbursement decisions, and significant investment in early cancer detection before it generates revenue. These challenges were presented alongside substantial growth momentum and a long-term plan to reach $6 billion in revenue.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Natera raised full-year revenue guidance to a range of $3.05 billion to $3.35 billion, up from $2.85 billion to $2.91 billion, an increase of $140 million at the midpoint and above $3 billion for the full year; the guide assumes steady ASPs and continued volume growth and does not include any true ups. Gross margins are expected to center at 64% to 66%, the top end of R&D was increased by $25 million, and the top end of SG&A was increased from $1.225 billion to $1.3 billion. For 2027, preliminary planning assumes the same number of units grown this year and ASP relatively steady, with a very modest assumption for true ups, gross margins in the same range as 2026, and OpEx growth in the 10% to 12% range next year, which should allow the company to continue to be cash flow generative. Natera set a goal to reach $6 billion in revenue in 2029, with several hundred million dollars of contribution from pharma and data in 2029, and said Signatera could reach $14.50 ASP versus current ASPs around $12.90, with a long term path to $2,000 ASP and beyond and a goal of 70% plus gross margins.
Natera Risk Analysis
Natera disclosed 55 risk factors in its most recent earnings report. Natera reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksNatera Peers Comparison
Overall Rating
CDNA75Outperform
BLLN70Outperform
VCYT70Outperform
MYGN53Neutral
GH44.3Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $3.92B | 29.89 | 34.08% | ― | 38.94% | 91.53% | |
| 70Outperform | $4.37B | 89.19 | 9.46% | ― | 71.90% | ― | |
| 70Outperform | $2.06B | 16.08 | 9.27% | ― | 17.50% | 311.25% | |
| 53Neutral | $530.45M | -4.05 | -40.40% | ― | -2.63% | 68.56% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $19.64B | -39.44 | 249.03% | ― | 41.69% | -14.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:45E | Natera Inc. | 258.00 | 100.00 | 63.29% | |
| MYGN | Myriad Genetics | 5.53 | -1.85 | -25.07% | |
| VCYT | Veracyte Inc | 25.57 | -18.44 | -41.90% | |
| CDNA | CareDx Inc | 74.44 | 57.26 | 333.29% | |
| GH | Guardant Health | 145.14 | 39.72 | 37.68% | |
| BLLN | BillionToOne, Inc. Class A | 91.54 | -18.46 | -16.78% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
